NEW YORK, Aug. 23, 2016 /PRNewswire/ -- Demy-Colton announced today a number of highly respected speakers participating at the 2016 Trans-Pacific Health Sciences Dialogue. The line-up includes top Asia experts who have real, on-the-ground experience operating in key markets such as China, Japan and South Korea.
- Paul Bolno, President and CEO, WAVE Life Sciences
- Yuan-Hua Ding, PhD, Pfizer External R&D Innovation (ERDI)-Asia Pacific, Pfizer Worldwide Research & Development
- Tim Opler, PhD, Partner, Torreya Partners
- Mark Tang, Head, WT Global Capital Inc.
- Brianne Weingarten, Head of Alliance Management, Licensing & Business Development, Purdue Pharma L.P.
- Wei Zhang, PhD, Investor, Lilly Ventures Asia
- Xiaoming Zou, Chief Business Officer, Eddingpharm
"Any responsible biopharmaceutical company looking to collaborate beyond the US has to look at Asia," says Sara Demy, Founder and CEO of Demy-Colton. "Key Asian countries are not only producing some of the best science in the world, the markets in Asia are predicted to account for a third of global pharmaceutical sales and to drive nearly half of all global incremental sales growth in the sector according to analyst IMS Health."
The Trans-Pacific Health Sciences Dialogue has earned a reputation as the best place for biotech companies to hone their trans-Pacific strategies. "This two-day event event will provide attendees with a solid grasp of Asian biopharmaceutical opportunities and today's best strategies for collaboration and partnering," explains Demy. "This meeting delivers critical insights that you simply won't get at any other meeting," Demy adds.
This year the event will be held September 28 – 29, 2016 at the Joseph B. Martin Conference Center at Harvard Medical School. "Moving the event to Boston gave us the opportunity to tap into a deeper vein of speakers who have 'been there and done that' in Asia," explains Dan Ruiz, Demy-Colton Chief Operating Officer.
About Trans-Pacific Health Sciences Dialogue
The Trans-Pacific Health Sciences Dialogue is a meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important trans-Pacific health care markets, including Japan, China, South Korea and North America.
Over the course of two days, executives, dealmakers, investors, professional advisors and KOLs with deep trans-Pacific experience will share their insights and experiences in an intimate and collegial setting that encourages interaction and collaboration. The program features informative panel discussions and case studies that focus on best practices to create growth, achieve objectives and add value and minimize risk on both sides of the Pacific.
About the Organizer
Since 2009, Demy-Colton has been developing and producing highly specialized targeted investor and business development conferences exclusively for the biopharmaceutical and life sciences industry. Its events are dedicated and designed to meet the needs of the leaders, investors and stakeholders of this rapidly developing sector as it comes of age.
Through its deep domain knowledge, it is able to bring together prominent thought leaders from industry and academia, key investors and global key opinion leaders to examine and address the opportunities and challenges the industry faces as it forges a future where it will indeed deliver on the promise of transformational science.
Tiberend Strategic Advisors, Inc.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/top-trans-pacific-biopharma-leaders-investors-advisors-featured-at-trans-pacific-health-sciences-dialogue-conference-300317234.html
SOURCE Demy-Colton Life Science Advisors